Biogen Inc. (NASDAQ BIIB) develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis. Biogen was founded in 1978 as one of the world’s first global biotechnology companies. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology.

Earnings were released today, January 25th, 2018 and estimates for 2018 are strong. With revenues believed to increase by $4 - $7 billion. This is paired with an estimate of lower R&D expenses and a lower tax rate.

Rationale
- Strong pipeline and presence in Biotech industry
- Expanding global influence
- Global leader in MS

Risks
- Competition
- Failure in early stage clinical trials
- Dependency on product sales

Future R&D Expectations
- **MS and Neuroimmunology**
  - BIIB908 Phase 3 in Multiple Sclerosis
- **Alzheimer’s Disease/Dementia**
  - BAN2401 Phase 2 in Alzheimer’s Disease
- **Neuromuscular Disorders**
  - BIIB167 Phase 1 in Amyotrophic Lateral Sclerosis
- **Movement Disorders**
  - BIIB106 Phase 1 in Parkinson’s Disease
- **Acute Neurology**
  - Natalizumab Phase 2b in Acute Ischemic Stroke
- **Pain**
  - BIIB074 Phase 2 in Painful Lumbar Sacral Radiculopathy
- **Ophthalmology**
  - BIIB007 Phase 1/2 in X-Linked Retinoschisis

Global Presence

Created by: Katie Perkner, Soraya Sartipi, Olivia Talbott